BCAB BioAtla
- 3.195
- +0.105+3.40%
BioAtla News
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance
BioAtla (BCAB) said Monday its investigational new drug application to assess BA3361 antibody drug conjugate to treat multiple tumor types has been cleared by the US Food and Drug Administration. The
Express News | BioAtla Announces FDA Clearance Of Investigational New Drug Application For BA3361
Express News | Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3361, a Cab-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability
GRIN, WOOF and MRNS Are Among After Hour Movers
Express News | JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Here's Why We're Watching BioAtla's (NASDAQ:BCAB) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Express News | BioAtla Shares Are Trading Higher After the Company Reported Q4 Financial Results
Q4 2023 Bioatla Inc Earnings Call
BioAtla Is Maintained at Buy by HC Wainwright & Co.
BioAtla Is Maintained at Buy by HC Wainwright & Co.
BioAtla Price Target Cut to $7.00/Share From $10.00 by HC Wainwright & Co.
BioAtla Price Target Cut to $7.00/Share From $10.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $7
HC Wainwright & Co. analyst Arthur He maintains BioAtla with a Buy and lowers the price target from $10 to $7.
BioAtla Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 138.1% HC Wainwright & Co. $10 → $7 Maintains Buy 12/05/2023 308.16% JMP Securities → $12 Reite
Optimistic Outlook for BioAtla's Pipeline Progression and Potential Partnerships
Earnings Call Summary | BioAtla(BCAB.US) Q4 2023 Earnings Conference
The following is a summary of the BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript:Financial Performance:BioAtla's Research and Development expenses for Q4 2023 were $22.7 million, increased from
Express News | BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
BioAtla: Q4 Earnings Insights
BioAtla (NASDAQ:BCAB) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsBioAtla beat estimated earnings by 28.99
BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results
Analysis
Price Target
No Data
